Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the route of ...

Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...

The number of patients who require maintenance on anticoagulation therapy (warfarin/Coumadin ®) for minimizing risk of cardiovascular events like stroke or thromboembolism is increasing.

For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure ...

Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

"Our goal is to provide a safer and superior blood thinner option for patients who rely on chronic anticoagulation but are underserved by current treatments. Warfarin, the first VKA anticoagulant ...

The most consistent anomalies are nasal hypoplasia and stippling of vertebrae or bony epiphyses. Management of pregnant patients on anticoagulation is challenging. Current guidelines suggest the use ...

(Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been recognized as the 2024 "Anticoagulation Therapy Company of ...

1 Despite strong evidence that treatment with direct oral anticoagulants prevents first ever stroke in people with atrial fibrillation, when to commence anticoagulation in patients with acute ...

The Johns Hopkins Anticoagulation Management Service is a collaboration between the Department of Hematology and Department of Pharmacy. The service is staffed by expert physician and pharmacists who ...